Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Cortés J[au]:

Search results

Items: 1 to 50 of 2165

1.

Corrigendum to "Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients" [Clin. Biomech. volume 68 (2019) Pages 169-174/Article Number JCLB 4795].

Olmos CMF, Alvarez-Calderon O, Marín DH, Cortés JI, Marco CP, Ivorra JAR.

Clin Biomech (Bristol, Avon). 2019 Nov 7. pii: S0268-0033(19)30813-7. doi: 10.1016/j.clinbiomech.2019.10.023. [Epub ahead of print] No abstract available.

PMID:
31708261
2.

The nucleus does not significantly affect the migratory trajectories of amoeba in two-dimensional environments.

De la Fuente IM, Bringas C, Malaina I, Regner B, Pérez-Samartín A, Boyano MD, Fedetz M, López JI, Pérez-Yarza G, Cortes JM, Sejnowski T.

Sci Rep. 2019 Nov 8;9(1):16369. doi: 10.1038/s41598-019-52716-2.

3.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2019 Nov 3. doi: 10.1002/ajh.25671. [Epub ahead of print]

PMID:
31682008
4.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

PMID:
31665578
5.

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.

Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, Cortés J, Moltó-Abad M, Muñoz-Delgado C, Pérez-Quintana M, Pérez-López J.

Orphanet J Rare Dis. 2019 Oct 21;14(1):230. doi: 10.1186/s13023-019-1202-6.

6.

Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study.

Hui R, Pearson A, Cortés J, Campbell C, Poirot C, Azim HA, Fumagalli D, Lambertini M, Daly F, Arahmani A, Pérez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G.

Clin Cancer Res. 2019 Oct 16. pii: clincanres.1164.2019. doi: 10.1158/1078-0432.CCR-19-1164. [Epub ahead of print]

PMID:
31619444
7.

Two S. pombe septation phases differ in ingression rate, septum structure, and response to F-actin loss.

Ramos M, Cortés JCG, Sato M, Rincón SA, Moreno MB, Clemente-Ramos JÁ, Osumi M, Pérez P, Ribas JC.

J Cell Biol. 2019 Oct 9. pii: jcb.201808163. doi: 10.1083/jcb.201808163. [Epub ahead of print]

PMID:
31597680
8.

Randomized phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.

Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mourón S.

Clin Cancer Res. 2019 Oct 9. pii: clincanres.2023.2019. doi: 10.1158/1078-0432.CCR-19-2023. [Epub ahead of print]

PMID:
31597662
9.

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.

Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F.

Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25648. [Epub ahead of print]

PMID:
31595534
10.

NK-lysin, dicentracin and hepcidin antimicrobial peptides in European sea bass. Ontogenetic development and modulation in juveniles by nodavirus.

Valero Y, Arizcun M, Cortés J, Ramírez-Cepeda F, Guzmán F, Mercado L, Esteban MÁ, Chaves-Pozo E, Cuesta A.

Dev Comp Immunol. 2019 Oct 5;103:103516. doi: 10.1016/j.dci.2019.103516. [Epub ahead of print]

PMID:
31593708
11.

Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.

Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, Cortes J, Pemmaraju N.

Br J Haematol. 2019 Nov;187(4):543-545. doi: 10.1111/bjh.16245. Epub 2019 Oct 4. No abstract available.

PMID:
31584727
12.

Corrigendum to: -PTEN activity defines an axis for plasticity at cortico-amygdala synapses and influences social behavior.

Sánchez-Puelles C, Calleja-Felipe M, Ouro A, Bougamra G, Arroyo A, Diez I, Erramuzpe A, Cortés J, Martínez-Hernández J, Luján R, Navarrete M, Venero C, Chan A, Morales M, Esteban JA, Knafo S.

Cereb Cortex. 2019 Sep 27. pii: bhz232. doi: 10.1093/cercor/bhz232. [Epub ahead of print] No abstract available.

PMID:
31560052
13.

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2019 Sep 25. doi: 10.1002/cncr.32504. [Epub ahead of print]

PMID:
31553487
14.

Comparison of polyspecific versus IgG specific ELISA in predominately cardiac patients with suspected heparin induced thrombocytopenia.

Samuel S, McGuire MF, Cortes J, Escobar M, Weeks P, Nguyen A.

J Thromb Thrombolysis. 2019 Sep 24. doi: 10.1007/s11239-019-01957-z. [Epub ahead of print]

PMID:
31552545
15.

Metastable Resting State Brain Dynamics.

Beim Graben P, Jimenez-Marin A, Diez I, Cortes JM, Desroches M, Rodrigues S.

Front Comput Neurosci. 2019 Sep 6;13:62. doi: 10.3389/fncom.2019.00062. eCollection 2019.

16.

Breast cancer.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F.

Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. Review.

PMID:
31548545
17.

Melioidosis in Colombia, description of a clinical case and epidemiological considerations

Rodríguez JY, Álvarez-Moreno CA, Cortés JA, Rodríguez GJ, Esquea K, Pinzón H, Mendoza MJ, Acosta Y.

Biomedica. 2019 May 1;39:10-18. doi: 10.7705/biomedica.v39i3.4534. English, Spanish.

18.

[Cambios significativos en el manejo y control del HIV/sida].

Cortés JA.

Biomedica. 2019 May 1;39:5-9. doi: 10.7705/biomedica.v39i0.5062. Spanish. No abstract available.

19.

Gata3-controlled nucleosome eviction drives Myc enhancer activity in T-cell development and leukemia.

Belver L, Yang AY, Albero R, Herranz D, Brundu FG, Quinn SA, Perez-Duran P, Alvarez S, Gianni F, Rashkovan M, Gurung D, Rocha PP, Raviram R, Reglero C, Cortes JR, Cooke AJ, Wendorff AA, Cordo V, Meijerink JP, Rabadan R, Ferrando AA.

Cancer Discov. 2019 Sep 13. pii: CD-19-0471. doi: 10.1158/2159-8290.CD-19-0471. [Epub ahead of print]

PMID:
31519704
20.

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.

Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA.

Future Oncol. 2019 Nov;15(31):3531-3545. doi: 10.2217/fon-2019-0373. Epub 2019 Sep 13.

21.
22.

A Reinforcement-Learning-Based Approach to Enhance Exhaustive Protein Loop Sampling.

Barozet A, Molloy K, Vaisset M, Siméon T, Cortés J.

Bioinformatics. 2019 Aug 29. pii: btz684. doi: 10.1093/bioinformatics/btz684. [Epub ahead of print]

PMID:
31504192
23.

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J.

Cancer Med. 2019 Nov;8(15):6559-6565. doi: 10.1002/cam4.2545. Epub 2019 Sep 10.

24.

Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory.

Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A, Gómez-Lado N, Ruibal Á, Aguiar P; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2019 Jul 30;84:1-8. doi: 10.1016/j.neurobiolaging.2019.07.014. [Epub ahead of print]

PMID:
31479859
25.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz I, Perelló A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Máhr K, Schenker M, Sohn J, Lee KS, Shepherd CJ, Oelmann E, Sarker SJ, Prendergast A, Marosics P, Moosa A, Lawrence C, Coetzee C, Mousa K, Cortés J.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2526. [Epub ahead of print]

PMID:
31465093
26.

Window of Opportunity trials for biomarker discovery in breast cancer.

Arnedos M, Roulleaux Dugage M, Perez-Garcia J, Cortes J.

Curr Opin Oncol. 2019 Nov;31(6):486-492. doi: 10.1097/CCO.0000000000000583.

PMID:
31464762
27.

Alginate as a support ligand for enhanced colloidal liquid aphron immobilization of proteins and drug delivery.

Ward K, Cortés JGC, Stuckey D.

Biotechnol Bioeng. 2019 Dec;116(12):3168-3178. doi: 10.1002/bit.27153. Epub 2019 Sep 9.

PMID:
31449332
28.

Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, Curigliano G, Bondarenko I, Yoon YC, Kim Y, Kim C.

Eur J Cancer. 2019 Oct;120:1-9. doi: 10.1016/j.ejca.2019.07.015. Epub 2019 Aug 21.

29.

The rise of oncology biosimilars: from process to promise.

Verrill M, Declerck P, Loibl S, Lee J, Cortes J.

Future Oncol. 2019 Oct;15(28):3255-3265. doi: 10.2217/fon-2019-0145. Epub 2019 Aug 23.

30.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-0508. [Epub ahead of print]

PMID:
31439579
31.

Trends of maxillofacial trauma: An update from the prospective register of a multicenter study in emergency services of Chile.

Werlinger F, Villalón M, Duarte V, Acevedo R, Aguilera R, Alcocer D, Badillo O, Briones R, Condal C, Del Río M, García R, Herrera M, Jaramillo J, Merchan F, Nasi M, Osbén R, Rivera A, Riviello S, Rojas P, Vidal C, Rodríguez G, Schild S, Arroyo E, Alvarado MJ, Sepúlveda P, Cortés J.

Med Oral Patol Oral Cir Bucal. 2019 Sep 1;24(5):e588-e594. doi: 10.4317/medoral.22985.

32.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C.

J Clin Oncol. 2019 Oct 10;37(29):2632-2642. doi: 10.1200/JCO.19.00416. Epub 2019 Aug 20.

PMID:
31430225
33.

Prematurity and ADHD in Childhood: An Observational Register-Based Study in Catalonia.

Perapoch J, Vidal R, Gómez-Lumbreras A, Hermosilla E, Riera L, Cortés J, Céspedes MC, Ramos-Quiroga JA, Morros R.

J Atten Disord. 2019 Aug 14:1087054719864631. doi: 10.1177/1087054719864631. [Epub ahead of print]

PMID:
31409171
34.

Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.

Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, DerSarkissian M, Cortina D, Narkhede S, Sheng Duh M.

Leuk Lymphoma. 2019 Aug 13:1-10. doi: 10.1080/10428194.2019.1644332. [Epub ahead of print]

PMID:
31409168
35.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.

Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.

PMID:
31400961
36.

Mist1 Expression Is Required for Paneth Cell Maturation.

Dekaney CM, King S, Sheahan B, Cortes JE.

Cell Mol Gastroenterol Hepatol. 2019 Jul 19;8(4):549-560. doi: 10.1016/j.jcmgh.2019.07.003. [Epub ahead of print]

37.

Approach to ocular toxoplasmosis including pregnant women.

Cortés JA, Roncancio Á, Uribe LG, Cortés-Luna CF, Montoya JG.

Curr Opin Infect Dis. 2019 Oct;32(5):426-434. doi: 10.1097/QCO.0000000000000577.

PMID:
31313714
38.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.

PMID:
31310323
39.

Genetics of Thyroid Disorders.

Cortés JMR, Zerón HM.

Folia Med (Plovdiv). 2019 Jun 1;61(2):172-179. doi: 10.2478/folmed-2018-0078. Review.

PMID:
31301652
40.

Catalyst Behavior in Metal-Catalyzed Carbonyl-Olefin Metathesis.

Hanson CS, Psaltakis MC, Cortes JJ, Devery JJ 3rd.

J Am Chem Soc. 2019 Jul 31;141(30):11870-11880. doi: 10.1021/jacs.9b02613. Epub 2019 Jul 22.

PMID:
31276383
41.

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.

Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S.

Am J Hematol. 2019 Oct;94(10):E256-E259. doi: 10.1002/ajh.25571. Epub 2019 Jul 28. No abstract available.

PMID:
31273842
42.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Jun 27:1-4. doi: 10.1080/10428194.2019.1633635. [Epub ahead of print] No abstract available.

PMID:
31246142
43.

Phylogeography and Population Genetics of Vicugna vicugna: Evolution in the Arid Andean High Plateau.

González BA, Vásquez JP, Gómez-Uchida D, Cortés J, Rivera R, Aravena N, Chero AM, Agapito AM, Varas V, Wheleer JC, Orozco-terWengel P, Marín JC.

Front Genet. 2019 Jun 6;10:445. doi: 10.3389/fgene.2019.00445. eCollection 2019.

44.

PTEN Activity Defines an Axis for Plasticity at Cortico-Amygdala Synapses and Influences Social Behavior.

Sánchez-Puelles C, Calleja-Felipe M, Ouro A, Bougamra G, Arroyo A, Diez I, Erramuzpe A, Cortés J, Martínez-Hernández J, Luján R, Navarrete M, Venero C, Chan A, Morales M, Esteban JA, Knafo S.

Cereb Cortex. 2019 Jun 26. pii: bhz103. doi: 10.1093/cercor/bhz103. [Epub ahead of print]

PMID:
31240311
45.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
46.

Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications.

Maurizi A, Capulli M, Curle A, Patel R, Ucci A, Côrtes JA, Oxford H, Lamandé SR, Bateman JF, Rucci N, Teti A.

Bone Res. 2019 Jun 11;7:17. doi: 10.1038/s41413-019-0055-x. eCollection 2019.

47.

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.

Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):509-515.e1. doi: 10.1016/j.clml.2019.05.008. Epub 2019 May 13.

48.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

PMID:
31209280
49.

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Shih YT, Cortes JE, Kantarjian HM.

Lancet Haematol. 2019 Aug;6(8):e398-e408. doi: 10.1016/S2352-3026(19)30087-0. Epub 2019 Jun 14.

PMID:
31208943
50.

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

Gavilá J, De La Haba J, Bermejo B, Rodríguez-Lescure Á, Antón A, Ciruelos E, Brunet J, Muñoz-Couselo E, Santisteban M, Rodríguez Sánchez CA, Santaballa A, Sánchez Rovira P, García Sáenz JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A.

Clin Transl Oncol. 2019 Jun 15. doi: 10.1007/s12094-019-02145-4. [Epub ahead of print]

PMID:
31203575

Supplemental Content

Loading ...
Support Center